Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: Evidence for induction of ligand-specific receptor states

Molecular Pharmacology

Volumn 66, Issue 1, 2004, Pages 97-105

  Gay, Elaine A ^b   Urban, Jonathan D ^b   Nichols, David E ^c   Oxford, Gerry S ^a,b   Mailman, Richard B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; DIHYDREXIDINE; DINAPSOLINE; DINOXYLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; POTASSIUM CHANNEL; POTASSIUM ION; PROPYLNORAPOMORPHINE; QUINPIROLE; UNCLASSIFIED DRUG; DOPAMINE D2L RECEPTOR; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL; PHENANTHRIDINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENANTIOMER; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; IN SITU HYBRIDIZATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RACEMIC MIXTURE; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECT; FEMALE; GENE EXPRESSION; HAMSTER; HUMAN; METABOLISM; PHOSPHORYLATION;

ANIMALS; CHO CELLS; CRICETINAE; CYCLIC AMP; DOPAMINE AGONISTS; FEMALE; FORSKOLIN; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; GENE EXPRESSION; HUMANS; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASES; PHENANTHRIDINES; PHOSPHORYLATION; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DOPAMINE D2;

EID: 3042630989     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.66.1.97     Document Type: Article

References (48)

1. Adham N, Ellerbrock B, Hartig P, Weinshank RL, and Branchek T (1993) Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptaminelb receptor expression system. Mol Pharmacol 43:427-433.
2. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104.
3. Brewster WK, Nichols DE, Watts VJ, Riggs RM, Mottola D, and Mailman RB (1995) Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b- hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands. J Med Chem 38:318-327.
4. s. J Pharmacol Exp Ther 294:539-547.
5. Chern YJ (2000) Regulation of adenylyl cyclase in the central nervous system. Cell Signal 12:195-204.
6. Choi EY, Jeong D, Won K, Park, and Baik JH (1999) G protein-mediated mitogen-activated protein kinase activation by two dopamine D2 receptors. Biochem Biophys Res Commun 256:33-40.
7. Cox RF, Neumeyer JL, and Waszczak BL (1988) Effects of N-n-propylnorapomorphine enantiomers on single unit activity of substantia nigra pars compacta and ventral tegmental area dopamine neurons. J Pharmacol Exp Ther 247:355-362.
8. o G proteins: evidence for agonist regulation of G protein selectivity. Br J Pharmacol 138:775-786.
9. 2 adrenergic receptor. J Biol Chem 276: 24433-24436.
10. Ghosh D, Snyder SE, Watts VJ, Mailman RB, and Nichols DE (1996) 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. J Med Chem 39:549-555.
11. Grubbs RA, Lewis MM, Owens-Vance C, Gay EA, Jassen AK, Mailman RB, and Nichols DE (2004) 8,9-Dihydro-1,2,3,11b-tetrahydrochromeno[4,3,2,-de] isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms. Bioorg Med Chem 12:1403-1412.
12. Gurwitz D and Haring R (2003) Ligand-selective signaling and high-content screening for GPCR drugs. Drug Discov Today 8:1108-1109.
13. Gurwitz D, Haring R, Heldman E, Fraser CM, Manor D, and Fisher A (1994) Discrete activation of transduction pathways associated with acetylcholine M1 receptor by several muscarinic ligands. Eur J Pharmacol 267:21-31.
14. Harper JF and Brooker G (1975) Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2′0 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res 1:207-218.
15. Hermans E (2003) Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol Ther 99:25-44.
16. 11] Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem 273:3097-3104.
17. Kenakin T (1995) Agonist-receptor efficacy. I: mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci 16:188-192.
18. Kenakin T (1997) Pharmacologic Analysis of Drug-Receptor Interaction, Lippincott-Raven, Philadelphia.
19. Kenakin T (2002) Drug efficacy at G protein-coupled receptors. Ann Rev Pharmacol Toxicol 42:349-379.
20. Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS, O'Malley KL, Todd RD, Blake BL, Nichols DE, and Mailman RB (2002) Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 301: 1179-1189.
21. Knoerzer TA, Nichols DE, Brewster WK, Watts VJ, Mottola D, and Mailman RB (1994) Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. J Med Chem 37:2453-2460.
22. Kudlacek O, Waldhoer M, Kassack MU, Nickel P, Salmi JI, Freissmuth M, and Nanoff C (2002) Biased inhibition by a suramin analogue of A1-adenosine receptor/G protein coupling in fused receptor/G protein tandems: the A1-adenosine receptor is predominantly coupled to Goalpha in human brain. Naunyn Schmiedeberg's Arch Pharmacol 365:8-16.
23. 2A-adrenoceptor responses in HEL 92.1.7 cells. Br J Pharmacol 132:1477-1484.
24. Kuzhikandathil EV and Oxford GS (2000) Dominant-negative mutants identify a role for GIRK channels in D3 dopamine receptor-mediated regulation of spontaneous secretory activity. J Gen Physiol 115:697-706.
25. 2L receptors couple to inward rectifier potassium channels in mammalian cell lines. Mol Cell Neurosci 12:390-402.
26. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, and Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627.
27. + channels. J Biol Chem 275:921-929.
28. Lopez-Ilasaca M (1998) Signaling From G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. Biochem Pharmacol 56:269-277.
29. Luo YQ, Kokkonen GC, Wang XT, Neve KA, and Roth GS (1998) D2 dopamine receptors stimulate mitogenesis through pertussis toxin-sensitive G proteins and Ras-involved ERK and SAP/JNK pathways in rat C6-D2L glioma cells. J Neurochem 71:980-990.
30. 2 dopamine receptors. Med Chem Res, in press.
31. Manning DR (2002) Measures of efficacy using G proteins as endpoints: differential engagement of G proteins through single receptors. Mol Pharmacol 62:451-452.
32. Missale C, Nash SR, Robinson SW, Jaber M, and Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
33. Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, et al. (2002) Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301:1166-1178.
34. O'Hara CM, Tang L, Taussig R, Todd RD, and O'Malley KL (1996) Dopamine D2L receptor couples to GαI2 and GαI3 but not GαI1, leading to the inhibition of adenylate cyclase in transfected cell lines. J Pharmacol Exp Ther 278:354-360.
35. Pohjanoksa K, Jansson CC, Luomala K, Marjamaki A, Savola JM, and Scheinin M (1997) Alpha2-Adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. Eur J Pharmacol 335:53-63.
36. Senogles SE (1994) The D2 dopamine receptor isoforms signal through distinct Gi α proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi a proteins. J Biol Chem 269:23120-23127.
37. Shapiro DA, Renock S, Arrington E, Sibley DR, Chiodo LA, Roth BL, and Mailman RB (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
38. Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, et al. (2002) (+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist. J Med Chem 45:3660-3668.
39. Smith HP, Nichols DE, Mailman RB, and Lawler CP (1997) Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur J Pharmacol 323:27-36.
40. Sugden PH and Clerk A (1997) Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. Cell Signal 9:337-351.
41. Versteeg HH, Nijhuis E, van den Brink GR, Evertzen M, Pynaert GN, van Deventer SJ, Coffer PJ, and Peppelenbosch MP (2000) A new phosphospecific cell-based ELISA for P42/P44 mitogen-activated protein kinase (MAPK), P38 MAPK, protein kinase B and CAMP-response-element-binding protein. Biochem J 350 Pt 3:717-722.
42. Watson C, Chen G, Irving P, Way J, Chen WJ, and Kenakin T (2000) The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. Mol Pharmacol 58:1230-1238.
43. Watts VJ, Lawler CP, Gonzales AJ, Zhou QY, Civelli O, Nichols DE, and Mailman RB (1995) Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists. Synapse 21:177-187.
44. Watts VJ, Wiens BL, Cumbay MG, Vu MN, Neve RL, and Neve KA (1998) Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells. J Neurosci 18:8692-8699.
45. Whistler JL, Chuang HH, Chu P, Jan LY, and von Zastrow M (1999) Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23:737-746.
46. Wickman KD, Iniguez-Lluhl JA, Davenport PA, Taussig R, Krapivinsky GB, Linder ME, Gilman AG, and Clapham DE (1994) Recombinant G-protein beta gamma-subunits activate the muscarinic-gated atrial potassium channel. Nature (Lond) 368:255-257.
47. Wiens BL, Nelson CS, and Neve KA (1998) Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations. Mol Pharmacol 54:435-444.
48. Zhou JY, Siderovski DP, and Miller RJ (2000) Selective regulation of N-type Ca channels by different combinations of G-protein beta/gamma subunits and RGS proteins. J Neurosci 20:7143-7148.